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Background: Coronary atherosclerosis, the most common form of coronary artery disease (CAD), is characterized by
accumulation of lipid in the walls of coronary arteries. Recent data from clinical trials have showed that high-density
lipoprotein cholesterol (HDL-C) has causal role in the pathogenesis and development of coronary atherosclerosis.
Cholesteryl ester transfer protein (CETP) is an important regulator of plasma HDL-C. Several genetic mutations in
the CETP gene were found to be associated with HDL-C levels. The aim of the present study is to evaluate the
association of HDL-C-related CETP polymorphisms and risk of coronary atherosclerosis.
Methods: We investigated the association of seven single nucleotide polymorphisms (SNP) (rs1800775, rs708272,
rs5882, rs1532624, rs1864163, rs7499892, and rs9989419) in the CETP gene with the risk of coronary atherosclerosis and
levels of HDL-C in a case–control study in China. Included in the study were 420 patients with coronary atherosclerosis
and 424 healthy controls. SNP genotyping was performed by TaqMan allelic discrimination assay and serum lipid levels
were measured by standard laboratory methods.
Results: Carriers of the AA and GA + AA genotypes of rs708272 had significant lower risks of coronary atherosclerosis
(OR = 0.55, 95% CI: 0.36-0.85, p = 0.003; OR = 0.67, 95% CI: 0.50-0.90, p = 0.007, respectively) compared to those with GG
genotype. These relations remained significant after adjustment for confounding effects of age, smoking, diabetes and
hypertension. The rs1800775 polymorphism was significantly associated with serum levels of HDL-C in healthy controls
(p = 0.04). Besides, rs708272 was in close linkage disequilibrium (LD) with rs1800775 in this study.
Conclusions: Our findings indicated that CETP rs708272 may be associated with the risk of coronary atherosclerosis
and rs1800775 may influence serum HDL-C levels in healthy controls in Chinese.
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Coronary atherosclerosis, a chronic inflammatory disease
characterized by the accumulation of fatty materials such
as cholesterol and triglyceride on the walls of the coronary
arteries, is the principal cause of coronary artery disease
(CAD) [1,2]. HDL is believed to be a protective factor
against CAD, and the inverse relationship between plasma
HDL-C and the incidence of CAD is well established [3,4].
Preliminary studies have suggested that HDL infusions
can induce atherosclerosis regression [5]. Protective effect
of HDL on atherosclerosis may due to its role in* Correspondence: zero991127@hotmail.com; agong62@126.com
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stated.preventing oxidation or other adverse effects of low-density
lipoprotein cholesterol (LDL-C) on endothelial cell, more-
over, HDL also can directly stimulate endothelial cell
to produce nitric oxide, beneficial anti-inflammatory,
anti-apoptotic and anti-thrombotic agents as well as
promote endothelial repair processes [6,7].
Cholesteryl ester transfer protein (CETP) is a hydro-
phobic glycoprotein, which has an established role in
transporting of cholesterol from the peripheral tissues to
the liver for elimination through exchanging triglycerides
of VLDL and LDL against cholesteryl esters of HDL.
The possibility that increased function of CETP might
be proatherogenic and that inhibition of its activity
might be antiatherogenic was first raised >20 years ago
[8]. CETP inhibitors as novel drugs have been developed
to raise HDL-C concentrations and improve HDL functiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and safety still need to be confirmed [9].
Several mutations in the CETP gene have been identi-
fied as a cause of CETP deficiency and change of HDL-C
levels, but the associations of these single nucleotide
polymorphisms (SNP) and susceptibility to atherosclerosis
still lacks consistency [10-12]. Besides, the relation between
these SNPs and risk of coronary atherosclerosis has not
been fully studied in Chinese population.
To help clarify whether the CETP SNPs which were
previously shown to be associated with plasma HDL-C
levels and also confirmed in a genome-wide association
study [10,13-17] are associated with susceptibility of
coronary atherosclerosis and plasma HDL-C levels, we
examined seven SNPs in the CETP gene (rs1800775,
rs708272, rs5882, rs1532624, rs1864163, rs7499892, and
rs9989419) in a case–control study in Chinese population.Results
Our study population consisted of 420 cases and 424
healthy controls. Characteristics of the study subjects
are shown in Table 1. Cases and controls were comparable
with respect to age and gender. Cases were more probably
to smoke cigarettes (50.9% vs. 32.3%), have diabetes
(21.0% vs. 12.0%) and hypertension (48.7% vs. 38.7%).
Besides, cases have significant lower levels of serum
HDL-C and higher levels of serum total cholesterol
(TC) and LDL-C than that in controls.
The associations of CETP variants with risk of coronary
atherosclerosis are presented in Table 2. The genotype
distributions of these seven variants showed no deviation
from the expected Hardy-Weinberg equilibrium among
controls (p > 0.05). Of these SNPs, carriers of the AA and
GA+AA genotypes of rs708272 had significant lower risk
of coronary atherosclerosis (OR = 0.55, 95% CI: 0.36-0.85,
p = 0.003; OR =0.67, 95% CI: 0.50-0.90, p = 0.007, re-
spectively) compared with carriers of the major genotype.
These associations remained statistically significant after
further adjustment for age, smoking, hypertension andTable 1 Selected characteristics of cases and controls







Total cholesterol (mmol/L) 4.72(4.11-5.48)
HDL-C (mmol/L) 1.20(1.09-1.51)
LDL-C (mmol/L) 2.83(2.47-3.29)diabetes. None of the other SNPs examined was associated
with coronary atherosclerosis.
Four SNPs in the CETP gene (rs1800775-rs1532624-
rs708272-rs1864163) were in linkage disequilibrium with
D’ ranging from 0.66 to 1.00 and r2 ranging from 0.07 to
0.55. However, we did not find any CETP haplotype that
was significantly associated with risk of coronary athero-
sclerosis (data not shown).
Finally, we investigated the associations between the
seven SNPs and serum HDL-C levels in 424 healthy
controls. In univariate analyses, CETP rs1800775 was
significantly associated with decreased serum level
of HDL-C (p = 0.04). Carriers of the mutant alleles of
rs1800775 (A/C: 1.45 ± 0.62 mmol/L; C/C: 1.28 ±
0.41 mmol/L) had significantly decreased serum HDL-C
levels compared with subjects with GG genotype (1.49 ±
0.72 mmol/L). When ANCOVA model was applied,
rs1800775 still showed significant association with HDL-C
level (p = 0.04). None of the other studied SNPs was
associated with serum HDL-C level (Table 3).
Discussion
Considering the crucial role of CETP in lipid metabolism,
we investigated the association of seven SNPs in this gene
and the risk of coronary atherosclerosis in a Chinese
population. Our results showed that rs708272 polymorph-
ism may reduce the risk of coronary atherosclerosis and
rs1800775 mutation may decrease serum HDL-C levels in
healthy controls in our population.
The human CETP gene is located on chromosome
16q21, and several mutations in this gene have been
reported to alter the function of CETP and plasma
HDL-C levels [10,13]. Among these SNPs, CETP TaqIB
site (rs708272) is the most studied one. The results of
prospective Women’s Genome Health Study (WGHS),
conducted in American women, showed that carriers of
B2B2 and B1B2 genotypes (56 mg/dL and 52 mg/dL)
had significant higher levels of plasma HDL-C than
carriers of B1B1 genotype (50 mg/dL) [10]. Moreover, a










Table 2 Association of genetic variants in CETP gene with
risk of coronary atherosclerosis
SNP Controls, n Cases, n OR (95% CI) P for trend
rs1800775
AA 116 102 1.00
AC 222 216 1.11(0.79-1.56)
CC 83 100 1.43(0.93-2.19) 0.32
AC + CC 305 316 1.19(0.86-1.65)
rs1532624
CC 199 209 1.00
CA 191 183 0.88(0.66-1.18)
AA 34 29 0.80(0.45-1.41) 0.52
CA + AA 225 212 0.87(0.65-1.16)
rs708272
GG 139 176 1.00
GA 207 192 0.71(0.52-0.97)
AA 74 50 0.55(0.36-0.85) 0.04
GA + AA 281 242 0.67(0.50-0.90)
rs1864163
GG 289 282 1.00
GA 116 115 1.05(0.76-1.44)
AA 18 23 1.49(0.75-2.93) 0.92
GA + AA 134 138 1.10(0.81-1.49)
rs7499892
GG 261 259 1.00
GA 136 138 1.06(0.78-1.45)
AA 27 24 0.96(0.53-1.75) 0.88
GA + AA 163 162 1.05(0.78-1.40)
rs5882
AA 142 135 1.00
AG 219 215 1.00(0.73-1.37)
GG 63 71 1.13(0.73-1.74) 0.89
AG + GG 282 286 1.03(0.76-1.39)
rs9989419
GG 198 201 1.00
GA 185 179 0.96(0.71-1.29)
AA 41 41 0.96(0.59-1.58) 0.71
GA + AA 226 220 0.96(0.72-1.27)
ORs: adjusted for age.
Table 3 Association between CETP polymorphisms and
serum HDL-C levels in health control subjects
SNP M/m HDL-C (mmol/L) mean ± SD P
MM Mm mm
rs1800775 A/C 1.49 ± 0.72 1.45 ± 0.62 1.28 ± 0.41 0.04
rs1532624 C/A 1.38 ± 0.51 1.45 ± 0.68 1.54 ± 0.80 0.27
rs708272 G/A 1.34 ± 0.55 1.46 ± 0.62 1.46 ± 0.70 0.15
rs1864163 G/A 1.43 ± 0.65 1.44 ± 0.57 1.22 ± 0.39 0.39
rs7499892 G/A 1.46 ± 0.65 1.39 ± 0.54 1.27 ± 0.64 0.23
rs5882 A/G 1.39 ± 0.61 1.46 ± 0.66 1.38 ± 0.48 0.49
rs9989419 G/A 1.46 ± 0.67 1.39 ± 0.57 1.42 ± 0.59 0.55
M indicates major allele; m indicates minor allele.
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had higher mean HDL-C concentrations and lower mean
CETP activity compared with carriers of B1 allele [13].
Besides, the relationship between TaqIB polymorphism
and HDL-C levels was also confirmed by other studies
[18,19]. But the association between CETP TaqIB and
CAD risk lacks consistency. A case–control study among
Singapore population [20] found that the absence of B2allele was associated with 2.0-fold increased risk of CAD,
but a meta-analysis revealed that B2B2 genotype had a
1.45-fold significant increased risk of CAD compared
with B1B1 genotype in population-based studies [21].
In our study, we also found that B2B2 genotype conferred
a significant reduced risk of coronary atherosclerosis
which had the same directions of risk with the previous
study done in Singapore population. In addition, controls
with B1B2 or B2B2 genotype had non-significant higher
level of serum HDL-C (1.46 ± 0.62 mmol/L and 1.46 ±
0.70 mmol/L) compared with the controls with B1B1
genotype (1.34 ± 0.55 mmol/L), which was in accordance
with the WGHS results. CETP TaqIB is located in intron
1 of CETP gene, and the functional phenotype of this
mutation is still unclear.
CETP -629C/A (rs1800775) is located in promoter re-
gion of the CETP gene, and this variation may influence
the functionality of CETP gene by changing in binding
site Sp1/Sp3 and in turn repress CETP promoter activity
[22,23]. Rs1800775 was found to be significantly associated
with plasma HDL-C levels in the WGHS with average
HDL-C (mg/dL) of 49 in CC carriers, 52 in CA carriers
and 55 in AA carriers [10]. The same tend of association
was also found among Latvian population [24]. In our
study, healthy controls carrying the CC genotype (1.28 ±
0.41 mmol/L) had significant lower level of HDL-C
compared with subjects with AA genotype (1.49 ±
0.72 mmol/L), which was consistent with previous
reports. Besides, we found CC genotype conferred a
non-significant elevated risk of coronary atheroscler-
osis (OR = 1.43, 95% CI = 0.93-2.19). Rs1800775 was in
high linkage disequilibrium with rs708272 in our study
(D’ = 0.97, r2 = 0.55), and this association was also sug-
gested by several other studies [10,25].
The exact mechanisms which may link CETP genetic
polymorphism to coronary atherosclerosis are largely un-
clear. But the linkage between CETP polymorphisms and
plasma HDL-C level may provide a possible mechanism that
merits further investigation. In addition, the limitation of
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pered our ability to detect some significant associations.
Conclusions
In conclusion, the present study demonstrating that the
A allele of the rs708272 may confer decreased risk of
coronary atherosclerosis, and rs1800775 may exert effect
on serum HDL-C levels in Chinese population. Future
studies with larger sample sizes as well as functional
studies are needed to confirm our findings.
Methods
Study subjects
A case–control study including 420 consecutive patients
with coronary atherosclerosis and 424 healthy controls
was carried out. Cases were collected from Jinling hospital
in Nanjing between June 2008 and May 2012. Clinical
diagnosis of coronary atherosclerosis was evaluated by
percutaneous coronary angiography, reviewed by two
experienced cardiologists. Healthy control subjects, with-
out coronary atherosclerosis, were selected in the same
period and from the same hospital, and were frequency
matched to the cases by age (5-year age groups) and
gender. All controls were individuals free of CAD that
determined by medical history, clinical examinations,
or electrocardiography. Those with coronary myocardial
bridge were excluded from the study. At enrollment,
demographic characteristics, anthropometric measures,
medical histories were collected from each subject by a
trained interviewer using a structured questionnaire.
Written informed consent was obtained from all enrolled
participants and this study was approved by the Ethics
Committee of Jinling hospital.
Laboratory tests
Blood samples were drawn for measurement of serum
levels of TC, HDL-C, LDL-C after a 12-hour overnight
fast. Serum levels of TC (mmol/L), HDL-C (mmol/L),
and LDL-C (mmol/L) were determined by colorimetric
enzymatic assays with use of an Auto-Analyzer (AU
2700 Olympus, FirstChemical Ltd, Tokyo, Japan).
Genotyping
Genomic DNA was extracted from peripheral blood
leucocytes using Promega DNA Extraction Kit (Promega,
Madison, WI, USA). Genotyping was performed using the
TaqMan assay on the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems, Foster City,
CA, USA), in a 384-well format, with dual fluorescent
reporter probes VIC and FAM. The genotyping call rate
was >95%, and the completion rate was >99%. The
quality and potential misclassification of the genotyping
were assessed by re-evaluating 5% of duplicate DNA
samples (42 total samples) that were randomly selectedfrom the whole population and placed within the same
reaction plates used for the study subjects. The con-
cordance rate for the quality control samples was 100%.
Statistical analysis
We used SAS software (version 9.3; SAS Institute, Inc.)
for the statistical analyses. χ2 statistics and the t test were
used to evaluate case–control differences in the distribution
of risk factors. Variables were tested for normality with
Shapiro-Wilk statistics. Skewed data, including age,
BMI, TC, HDL-C and LDL-C were log transformed and
expressed as medians and interquartile ranges. The
odds ratios (ORs) and 95% confidence intervals (CIs)
for the associations between the SNPs and disease risk
were estimated by unconditional logistic regression.
Hardy-Weinberg equilibrium for genotypic distribution
and linkage disequilibrium between loci were assessed
by HaploView version 4.0 (Daly Lab at the Broad Institute,
Cambridge, MA, USA) [26]. Associations between hap-
lotypes (> 1% frequency) and the risk of coronary ath-
erosclerosis were evaluated by computing OR and 95%
CI using HAPSTAT, assuming an additive model, using
the most common haplotype as the referent category
[27]. Both univariate ANOVA and multivariate ANCOVA
analyses adjusting for age, smoking, diabetes and hyper-
tension were performed to determine the effects of the
CETP polymorphisms on serum HDL-C levels. A two
tailed P-value of 0.05 was considered statistically significant.
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